Analysis of carbohydrate containing biosimilars

Biosimilares/Investigación | Posted 31/10/2013 post-comment0 Post your comment

During a presentation given by Dr Azadi Parastoo, University of Georgia, GA, USA, at the international conference on biowaivers and biosimilars, held in the US in September 2012, the types of analytical techniques that can be utilized in order to characterize differences in glycosylation for analysis of biosimilars were discussed [1].

picture 150

One topic highlighted was the complexity of glycosylation states of low molecular weight heparin and the differences observed in sialic acid incorporation with process changes. This topic is significant to biosimilar production and may pose many challenges to the bioanalytical scientist due to differences observed in calibration curve performance and quality control recovery.

Relevant to this topic is the use of transgenic plants to produce monoclonal antibodies. This poses a risk to glycosylation patterns due to the unique pathways and carbohydrates that plants produce, including 1,3-fucose and 1,2-xylose.

Glycosylation is an enzymatic process in which a carbohydrate is attached to a hydroxyl or other functional group of another molecule. It is a form of co-translational and post-translational modification. Glycosylation is important as it can be a cause of unwanted immunogenicity in both biologicals and biosimilars.

Related articles

Immunogenicity testing in biosimilars

Protein aggregation and the generation of immune responses

Bioanalytical challenges in the development of biosimilars

Reference

1.  Colletti KS. Conference Report: Bioanalysis-related topics presented at the International Conference and Exhibition on Biowaivers and Biosimilars. Bioanalysis. 2013;5(5):529-31.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010